References 1.AS Go, EM Hylek, KA Philips, Y Chang, LE Henault, JV Selby, DE Singer.revalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation...
Reddy VY, Akehurst RL, Armstrong SO, Amorosi SL, Brereton N, Hertz DS, et al. Cost effectiveness of left atrial appendage closure with the Watch- man device for atrial fibrillation patients with absolute contraindications to warfarin. Europace. 2016;18:979-86....
Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin Atrial fibrillation (AF) patients with contraindications to oral anticoagulation have had few options for stroke prevention. Recently, a novel oral anticoa...
The Watchman device is therefore a real step forward, in that it offers an alternative to oral anticoagulation therapy for thromboembolic prevention in patients with nonvalvular atrial fibrillation." The Watchman device seals off the left atrial appendage in the heart, which is the major source of...
(LAAC) Device. Designed to further advance the procedural performance and safety of the WATCHMAN technology, which is indicated to reduce stroke risk in patients with non-valvular atrial fibrillation (NVAF) who need an alternative to oral anticoagulation therapy, the device now features a polymer ...
The Watchman (Boston Scientific, MA) is a percutaneous left atrial appendage closure (LAAC) device which has been tested prospectively in multiple randomized trials. It offers a new stroke risk reduction option for high-risk patients with non-valvular atrial fibrillation who are seeking an ...
Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin Atrial fibrillation (AF) patients with contraindications to oral anticoagulation have had few options for stroke prevention. Recently, a novel oral anticoa...
Medicare spending is concentrated among a few high-cost beneficiaries who are often targeted by cost-saving interventions. The Continuous Medicare History ... Riley,F G. - 《Health Affairs》 被引量: 185发表: 2007年 Outcomes of Medicare beneficiaries with ventricular assist devices. To the Editor...
Annually, 800,000 strokes occur in the U.S., with 1.5 % of these attributed to AF for those under 59 and 23 % of those >80 years of age [3]. Stroke is the third leading cause of death and the number one cause of major morbidity in the U.S. and is estimated to cost the ...
Cost effectiveness of left atrial appendage closure with the Watch- man device for atrial fibrillation patients with absolute contraindications to warfarin. Europace. 2016;18:979-86.Reddy VY, Akehurst RL, Armstrong SO, et al. Cost effec- tiveness of left atrial appendage closure with the Watchman...